We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vermont Gov. Peter Shumlin signed into law Friday a transparency bill that would require certain drugmakers to justify their price increases for specific products. Read More
Despite a surge in new oncology therapies in the past five years, a new report says that access to many of these drugs is limited to only a handful of countries. Read More
The UK’s National Institute for Health and Care Excellence refused to recommend Janssen’s chronic lymphocytic leukemia treatment Imbruvica for reimbursement on Wednesday, but left the door open to further discussion. Read More
Two House Republicans are accusing the FDA of shirking its responsibility when it comes to explaining the limits of off-label promotion, leaving it up to the courts to decide the matter for it. Read More
Fifteen House Democrats are calling on top U.S. trade officials to clarify the administration’s position on compulsory licensing for Novartis’ cancer drug Gleevec in Colombia. Read More
A U.S. district court has dismissed patent infringement claims against Hikma Pharmaceuticals, ruling that Takeda Pharmaceuticals USA lacked any “plausible claim to relief” in the case. Read More
In an effort to lower prescription drug spending, China is slashing prices for three drugs by more than 50 percent, a move that will hit both GlaxoSmithKline and AstraZeneca in the wallet. Read More